FFA
GALT icon

Farther Finance Advisors’s Galectin Therapeutics GALT Stock Holding History

Farther Finance Advisors’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$19 Buy
+5
New +$19 ﹤0.01% 6073
2023
Q4 		– Sell
-350
Closed -$672 – 3569
2023
Q3 		$672 Buy
+350
New +$576 ﹤0.01% 2188

Other funds holding GALT

AP
Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Farther Finance Advisors's GALT Position: Q3 2026 in Review

Farther Finance Advisors opened a new position in Galectin Therapeutics (GALT) in Q3 2026: 5 shares worth $19. The stake represents ﹤0.01% of the portfolio and ranks #6073 among its holdings. This is a return to the name: Farther Finance Advisors previously reported a position in GALT as recently as Q3 2023.

Farther Finance Advisors first reported a position in GALT in Q3 2023 and has held it in 2 quarters since. The position peaked at $672 in Q3 2023. 4 funds tracked by Wall St. Rank hold GALT as of Q3 2026.

  • Farther Finance Advisors held 5 shares of Galectin Therapeutics worth $19 as of Q3 2026.
  • Galectin Therapeutics was a new Farther Finance Advisors position in Q3 2026.
  • Galectin Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #6073 holding.
  • Farther Finance Advisors first reported a position in Galectin Therapeutics in Q3 2023 and has held it in 2 quarters since.
  • Farther Finance Advisors's Galectin Therapeutics position peaked at $672 in Q3 2023.
  • 4 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.